Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis

Oncotarget

Volumn 8, Issue 14, 2017, Pages 23880-23890

  Kang, Weiting ^a,b   Cui, Zilian ^a,b   Chen, Qianqian ^a,b   Zhang, Dong ^a   Zhang, Haiyang ^a   Jin, Xunbo ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Narrow band imaging; Non muscle invasive bladder cancer; Recurrence risk; Resection; White light imaging

Indexed keywords

CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; NARROW BAND IMAGING ASSISTED TRANSURETHRAL RESECTION; NON MUSCLE INVASIVE BLADDER CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK REDUCTION; SURVIVAL RATE; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; WHITE LIGHT IMAGING ASSISTED TRANSURETHRAL RESECTION; BLADDER TUMOR; DIAGNOSTIC IMAGING; INFORMATION PROCESSING; PREVENTION AND CONTROL; RISK FACTOR; TUMOR RECURRENCE;

DATA COLLECTION; HUMANS; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 85016998973     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13054     Document Type: Review

References (47)

1. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005; 66: 4-34.
2. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. 2010 Lyon, France: International Agency for Research on Cancer; 2013. Available from: globocan.iarc.fr.
3. Goh AC, Lerner SP. Application of new technology in bladder cancer diagnosis and treatment. World J Urol. 2009; 27: 301-307.
4. Herr HW. Natural history of superficial bladder tumors: 10-to 20-year follow-up of treated patients. World J Urol. 1997; 15: 84-88.
5. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Busch C, Johansson SL. Recurrence and progression in low grade papillary urothelial tumors. J Urol. 1999; 162: 702-707.
6. Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, Newling D, Bouffioux C, Sylvester RJ. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002; 41: 523-531.
7. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DWW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49: 466-477.
8. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodríguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000; 163: 73-78.
9. Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int. 2008; 102: 1111-1114.
10. Liu JJ, Droller MJ, Liao JC. New optical imaging technologies for bladder cancer: considerations and perspectives. J Urol. 2012; 188: 361-368.
11. Cauberg ECC, Kloen S, Visser M, De La Rosette JJMCH, Babjuk M, Soukup V, Pesl M, Duskova J, De Reijke TM. Narrow band imaging cystoscopy improves the detection of nonmuscle-invasive bladder cancer. Urology. 2010; 76: 658-663.
12. Herr HH. Narrow band imaging cystoscopy. Urol Oncol. 2011; 29: 353-357.
13. Hirata I, Nakagawa Y, Ohkubo M, Yahagi N, Yao K. Usefulness of magnifying narrow-band imaging endoscopy for the diagnosis of gastric and colorectal lesions. Digestion. 2012; 85: 74-79.
14. Kuznetsov K, Lambert R, Rey JF. Narrow-band imaging: potential and limitations. Endoscopy. 2006; 38: 76-81.
15. Wong Kee Song LM, Adler DG, Conway JD, Diehl DL, Farraye FA, Kantsevoy SV, Kwon R, Mamula P, Rodriguez B, Shah RJ, Tierney WM. Narrow band imaging and multiband imaging. Gastrointest Endosc. 2008; 67: 581-589.
16. Klän R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol. 1991; 146: 316-318.
17. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999; 162: 74-76.
18. Kolozsy Z. Histopathological 'self control' in transurethral resection of bladder tumours. Br J Urol. 1991; 67: 162-164.
19. Divrik RT, Yildirim üt, Zorlu F, özen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006; 175: 1641-1644.
20. Shen Y-J, Zhu Y-P, Ye D-W, Yao X-D, Zhang S-L, Dai B, Zhang H-L, Zhu Y. Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a 'second look' matters? Int Urol Nephrol. 2012; 44: 451-457.
21. Zhu Y-P, Shen Y-J, Ye D-W, Wang C-F, Yao X-D, Zhang S-L, Dai B, Zhang H-L, Shi G-H. Narrow-band imaging flexible cystoscopy in the detection of clinically unconfirmed positive urine cytology. Urol Int. 2011; 88: 84-87.
22. Cauberg ECC, Mamoulakis C, de la Rosette JJMCH, de Reijke TM. Narrow band imaging-assisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate. World J Urol. 2011; 29: 503-509.
23. Naselli A, Introini C, Timossi L, Spina B, Fontana V, Pezzi R, Germinale F, Bertolotto F, Puppo P. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscleinvasive bladder cancer recurrence. Eur Urol. 2012; 61: 908-913.
24. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151: 264-269.
25. Geavlete B, Multescu R, Georgescu D, Stanescu F, Jecu M, Geavlete P. Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology. 2012; 79: 846-851.
26. Herr HW. Randomized trial of narrow-band versus whitelight cystoscopy for restaging (second-look) transurethral resection of bladder tumors. Eur Urol. 2015; 67: 605-608.
27. Kobatake K, Mita K, Ohara S, Kato M. Advantage of transurethral resection with narrow band imaging for nonmuscle invasive bladder cancer. Oncol Lett. 2015; 10: 1097-1102.
28. Ma T, Wang W, Jiang Z, Shao G, Guo L, Li J, Zhang L, Liu Y. Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. National Medical Journal of China. 2015; 95: 3032-3035.
29. Stanescu F, Geavlete B, Georgescu D, Jecu M, Moldoveanu C, Adou L, Bulai C, Ene C, Geavlete P. NBI-plasma vaporization hybrid approach in bladder cancer endoscopic management. J Med Life. 2014; 7: 155-159.
30. Jakse G, Algaba F, Malmström P-U, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol. 2004; 45: 539-546.
31. Babjuk M, Soukup V, Petrík R, Jirsa M, Dvorácek J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 2005; 96: 798-802.
32. Lee CSD, Yoon CY, Witjes JA. The past, present and future of cystoscopy: the fusion of cystoscopy and novel imaging technology. BJU Int. 2008; 102: 1228-1233.
33. Al'-Shukri S, Danil'chenko DI, Kënig F, Shnorr D. [ALA fluorescent diagnosis of bladder cancer]. Urologiia. 2000. 48-50.
34. Cauberg ECC, Kloen S, Visser M, de la Rosette JJMCH, Babjuk M, Soukup V, Pesl M, Duskova J, de Reijke TM. Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. Urology. 2010; 76: 658-663.
35. Hafner C, Knuechel R, Zanardo L, Dietmaier W, Blaszyk H, Cheville J, Hofstaedter F, Hartmann A. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene. 2001; 20: 4910-4915.
36. Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, Nseyo U, Droller MJ. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007; 178: 62-67.
37. Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, Droller MJ. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007; 178: 68-73.
38. Daniltchenko DI, Riedl CR, Sachs MD, Koenig F, Daha KL, Pflueger H, Loening SA, Schnorr D. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol. 2005; 174: 2129-2133.
39. Lee JY, Cho KS, Kang DH, Jung HD, Kwon JK, Oh CK, Ham WS, Choi YD. A network meta-analysis of therapeutic outcomes after new image technologyassisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. BMC Cancer. 2015; 15: 566.
40. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer. Pharmacoeconomics. 2003; 21: 1315-1330.
41. Avritscher EBC, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, Elting LS. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006; 68: 549-553.
42. Cheung G, Sahai A, Billia M, Dasgupta P, Khan MS. Recent advances in the diagnosis and treatment of bladder cancer. BMC Med. 2013; 11: 1-8.
43. Grimbergen MCM, van Swol CFP, Jonges TGN, Boon TA, van Moorselaar RJA. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol. 2003; 44: 51-56.
44. Jocham D, Stepp H, Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol. 2008; 53: 1138-1150.
45. Gono K, Obi T, Yamaguchi M, Ohyama N, Machida H, Sano Y, Yoshida S, Hamamoto Y, Endo T. Appearance of enhanced tissue features in narrow-band endoscopic imaging. J Biomed Opt. 2004; 9: 568-577.
46. Song PH, Cho S, Ko YH. Decision based on narrow band imaging cystoscopy without a referential normal standard rather increases unnecessary biopsy in detection of recurrent bladder urothelial carcinoma early after intravesical instillation. Cancer Res Treat. 2016; 48: 273-280.
47. Tatsugami K, Kuroiwa K, Kamoto T, Nishiyama H, Watanabe J, Ishikawa S, Shinohara N, Sazawa A, Fukushima S, Naito S. Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. J Endourol. 2010; 24: 1807-1811.